Philip Morris International Inc. (NYSE: PM) beat earnings estimates for the third quarter of 2019 but revenues missed expectations. Shares were up by 1.1% in premarket hours on Thursday.
Total revenues of $7.64 billion rose 1.8% from last year but fell slightly below forecasts of $7.67 billion.
Reported EPS fell 15.3% year-over-year to $1.22 while adjusted EPS dropped 0.7% to $1.43. Analysts had projected adjusted EPS of $1.36.
During the quarter, cigarette and heated tobacco unit shipment volume fell by 2.1%. Cigarette shipment volume was down by 5.9% while heated tobacco unit shipment volume was up by 84.8%. The market share of heated tobacco units in IQOS markets, excluding the US, rose by 1.3 points to 5.1%.
Andre Calantzopoulos, CEO, said, “The exciting global growth of our heated tobacco products drove our resilient total shipment performance, despite certain timing issues related to our combustible portfolio.”
Cigarette shipment volumes declined across all geographic regions while heated tobacco unit shipments increased across all regions, barring the Middle East and Africa, which saw a drop of 49%. The increase in heated tobacco unit shipment volume was mainly driven by the EU, notably Italy, Eastern Europe, notably Kazakhstan, Russia and Ukraine, as well as Japan.
Also read: Philip Morris International Q3 2019 Earnings Preview
In the third quarter, revenues increased across most regions except for the Middle East and Latin America regions.
For the full year of 2019, Philip Morris lowered its reported EPS guidance to at least $4.73 versus the prior outlook of at least $4.94. Adjusted EPS is expected to be $5.14. The company expects total cigarette and heated tobacco unit shipment volume for PMI to decline approx. 1% to 1.5% on a like-for-like basis, versus the earlier outlook for a decline of approx. 1%. This is mainly due to the impact of price increases in select markets.
Philip Morris increased its regular quarterly dividend by 2.6% to an annualized rate of $4.68 per common share.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on